drugset / Trial / NCT03426540
Intravitreal Conbercept After Vitrectomy
RandomizedParallel-groupSingle-blindTreatment
Summary
To evaluate the safety and efficacy of intravitreal conbercept after vitrectomy for the management of early-stage proliferative diabetic retinopathy (PDR). Hypothesis: intravitreal conbercept therapy may promote functional and anatomic recovery from PDR. intravitreal conbercept therapy may be a useful and safe method for improving visual outcomes of surgery for early-stage PDR.
Timeline
- Start
- 2017-01-01
- Primary completion
- 2018-03-30
- Completion
- 2019-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Conbercept | Protein / enzyme biologic | 0.5 mg | Intravitreal |